Genetic evaluation should be part of retinoblastoma care

Results of a study by Baylor College of Medicine physicians underscore the important role that clinical genetic evaluation can have in the management plan of patients with retinoblastoma, a childhood cancer of the eye.

The report documents the success of using a multi-disciplinary team approach to achieving the goal of providing genetic evaluation and testing of all retinoblastoma patients at Texas Children's over an eight-year period. Results were published in the Archives of Ophthalmology.

"Integrating genetic evaluation into retinoblastoma care helps in understanding whether the disease is inherited or not, and being armed with that information is important for patient screening as well as for determining at-risk relatives," said Dr. Shweta Dhar, assistant professor of molecular and human genetics and director of the adult genetics program at BCM, lead author of the paper.

Retinoblastoma affects about 350 infants and children in the United States each year and is the most common of the eye in children. Retinoblastoma is often curable, but may result in the loss of the eye.

The disease takes two forms. Bilateral retinoblastoma is inherited and can affect one or both eyes and is often seen in infants and younger children. Unilateral retinoblastoma affects only one eye and generally occurs in older children. It may or may not be hereditary.

The clinical team including ophthalmologists, pediatric oncologists, pathologists, geneticist and genetic counselors completed genetic evaluation of nearly 65 percent of patients. Testing that included both DNA sequencing and other more advanced tests, such as copy number analysis, resulted in a higher yield. Overall, the demonstrated the causative mutation in 90 percent of patients with bilateral retinoblastoma and documented the hereditary form of retinoblastoma in 17 percent of patients with unilateral retinoblastoma.

Knowing whether the patient's disease is hereditary helps determine whether the patient is at increased risk for other cancers in the future.

In addition, genetic results from retinoblastoma patients led to the testing of 46 at-risk relatives, mostly parents and siblings. These tests determined that only six carried the mutation and required follow-up screening by an ophthalmologist. Forty relatives who underwent genetic testing were negative and do not require extensive screening.

"Without genetic testing, most relatives, particularly infant siblings, of retinoblastoma patients undergo eye examinations under anesthesia to screen for tumors," explained Dr. Sharon Plon, professor of pediatrics – hematology/oncology and of molecular and at BCM and senior author of the study. "What we were able to show is that by systematically including in the care of retinoblastoma we could eliminate the need for such screening in the majority of relatives and save both health care costs and potential risks of the anesthesia."

More information: Arch Ophthalmol. 2011;129[11]:1428-1434.

add to favorites email to friend print save as pdf

Related Stories

Possible new heritable marker for retinoblastoma

Jan 26, 2010

Retinoblastoma is a pediatric eye cancer initiated by the loss or mutation of both copies of the retinoblastoma gene. Current evidence suggests that additional genetic alterations are required for retinoblastoma to become ...

Why mice don’t get cancer of the retina

May 03, 2006

Humans are more susceptible to developing the eye cancer retinoblastoma than mice because, unlike humans, mice can compensate for the loss of activity of a gene critical to normal retinal development , according ...

Potential new eye tumor treatment discovered

Aug 05, 2011

New research from a team including several Carnegie scientists demonstrates that a specific small segment of RNA could play a key role in the growth of a type of malignant childhood eye tumor called retinoblastoma. The tumor ...

Recommended for you

User comments